Vincerx Pharma Inc


Vincerx Pharma Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.96
  • Today's Change-0.010 / -1.02%
  • Shares traded19.54k
  • 1 Year change-77.57%
  • Beta--
Data delayed at least 15 minutes, as of Mar 21 2023 20:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Vincerx Pharma, Inc. is a clinical-stage life sciences company that is focused on the development and oncology knowledge to advance new therapies to address unmet medical needs for the treatment of cancer. The Company’s small molecule drug program includes VIP152, which is a selective, clinical-stage positive transcription elongation factor-beta/cyclin-dependent kinase 9 (PTEFb/CDK9) inhibitor. The Company's antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors. Its SMDC platform targets advanced solid tumors with optimized camptothecin, a potent cytotoxin (warhead, payload or toxophore).

  • Revenue in USD (TTM)0.00
  • Net income in USD-58.20m
  • Incorporated2018
  • Employees56.00
  • Location
    Vincerx Pharma Inc260 Sheridan Avenue, Suite 400PALO ALTO 94306United StatesUSA
  • Phone+1 (650) 800-6676
  • Fax+1 (302) 655-5049
  • Websitehttps://vincerx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Aeglea Bio Therapeutics Inc2.33m-83.82m19.62m69.00--0.3897--8.42-1.03-1.030.02760.76980.0257--3.9133,753.63-92.58-71.18-114.60-83.92-----3,598.76-1,414.93----0.0003---87.57-14.86-27.38---42.77--
Modular Medical Inc0.00-14.88m19.67m0.00--2.45-----1.50-1.500.000.73390.00-------313.62-----------------26.190.00-------152.55------
Paranovus Entertainment Technology Ltd89.49m-49.19m19.70m218.00--0.9845--0.2201-21.95-21.9544.215.060.851654.032.89410,498.40-51.41-1.15-61.75-1.344.1532.41-60.37-1.263.08--0.0285--25.1911.05-6,355.48--17.03--
Skye Bioscience Inc0.00-12.10m19.74m9.00---------0.0244-0.02440.00-0.00660.00----0.00-166.29-295.95-350.36-------------18.94---------29.90--52.22--
Lucy Scientific Discovery Inc0.00-5.89m20.26m-----------0.3617-0.36170.00-0.3532---------------------------1.68---------23.92------
Comera Life Sciences Holdings Inc-100.00bn-100.00bn20.30m11.00--------------0.0603----------------------------0.00---27.79---156.50------
Vincerx Pharma Inc0.00-58.20m20.55m56.00--0.3442-----2.77-2.770.002.820.00----0.00-57.68---69.83--------------0.00-------136.50------
Forte Biosciences Inc0.00-12.34m20.67m6.00--0.4826-----0.7855-0.78550.002.040.00----0.00-26.68-67.80-28.54-82.40-------1,212.36----0.00------53.30------
DSwiss Inc2.30m180.35k20.69m9.00113.64100.4777.349.010.00090.00090.01110.0015.4188.7123.76255,042.2048.78-31.31144.68-85.6726.8628.779.01-19.451.7438.330.2218--45.3370.191,550.39--2.46--
Endexx Corp1.18m-17.54m20.76m--------17.57-0.0351-0.03510.0024-0.04480.71850.3827.82---1,066.01------70.09---1,483.77--0.0122-0.2837-----43.43--25.70------
Zynerba Pharmaceuticals Inc0.00-35.83m21.23m28.00--0.4024-----0.866-0.8660.001.120.00----0.00-47.04-54.20-54.28-63.35-------225,015.00---81.790.00------27.33---15.38--
Neurosense Therapeutics Ltd-100.00bn-100.00bn21.25m11.00--2.71----------0.6721----------------------------0.0216-------42.89------
ABVC Biopharma Inc343.00k-19.49m21.35m28.00--3.58--62.26-0.6934-0.69340.01160.18140.030.59161.3212,250.00-163.89---223.68--93.06---5,455.63--0.7402--0.2469---26.34---31.13------
Edesa Biotech Inc0.00-15.51m21.66m16.00--2.03-----0.9996-0.99960.000.53080.00----0.00-129.11---147.73--------------0.00-------31.52---54.88--
CASI Pharmaceuticals Inc37.01m-27.08m21.71m168.00--0.3594--0.5868-1.97-1.972.694.540.28024.094.12220,273.80-19.92-35.38-29.22-43.3358.51---71.10-337.701.68--0.0348--99.25--24.09--133.52--
Data as of Mar 21 2023. Currency figures normalised to Vincerx Pharma Inc's reporting currency: US Dollar USD

Institutional shareholders

48.29%Per cent of shares held by top holders
HolderShares% Held
Goldman Sachs & Co. LLC (Private Banking)as of 31 Jan 20232.15m10.14%
Sage Rhino Capital LLCas of 31 Dec 20221.69m7.96%
Affinity Asset Advisors LLCas of 31 Dec 20221.49m7.05%
Long Focus Capital Management LLCas of 31 Dec 20221.41m6.68%
Rock Springs Capital Management LPas of 31 Dec 2022891.72k4.21%
Citadel Advisors LLCas of 31 Dec 2022623.93k2.94%
Schonfeld Strategic Advisors LLCas of 31 Dec 2022573.25k2.71%
The Vanguard Group, Inc.as of 31 Dec 2022514.31k2.43%
Sabby Management LLCas of 31 Dec 2022500.00k2.36%
Rubric Capital Management LPas of 31 Dec 2022386.72k1.83%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.